If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 11 - 20 of 279
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Objective
Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Protocol No
MERCK-MK-5684-01A
Categories
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Periphera
Objective
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Protocol No
TSCAN-001
Categories
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
Objective
CVN424 in Parkinson's Disease Participants With Motor Complications
Protocol No
NEURO-CEREVANCE-CVN424-301
Establishing an AI-based Foundation for Remote Automated Speech and Language Therapy in Aphasia
Objective
PIC NAME AI
Protocol No
NEURO-IIT-ANDERSON-PICNAMEAI
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Objective
Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Recipients
Protocol No
SURG-BIOGEN-TRANSCEND
Categories
The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (the "EMAGINE 2.0" Study)
Objective
Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment - EMAGINE 2.0
Protocol No
PMR-BRAINQ-EMAGINE-2
Categories
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients A
Objective
Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Protocol No
SWOG-MM1YA-S01
Categories
A Phase 1, Multicenter, First-in-Human Study of DS-1471A in Subjects with Advanced Solid Tumors
Objective
The purpose of this study is to learn more about an investigational drug called DS-1471a. DS-1471a is an investigational drug that is not approved for your disease by health authorities, such as the U.S. Food and Drug Administration (FDA). It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS1471-079
Phase I Study of Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
Objective
Phase I Study of Iadademstat with Azacitidine in Patients with Myelodysplastic Syndrome
Protocol No
IIT-GURU-IADADEMSTAT-MDS
Categories
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Objective
Oral Upadacitinib in Adults with Mild to Moderate SLE
Protocol No
RHEU-ABBVIE-SELECT-SLE
Categories